C-88QKRefoxy Pharma
FOXO3 modulation, cellular resilience, age-related disease therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-88QK
C-88QKC-88QKFOXO3 modulation, cellular resilience, age-related disease therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Imagine living a long and healthy life. Imagine not getting sick at all at 80 years old, or who knows, maybe 100 years old. The possibilities are endless thanks to today’s advancements in science and technology, and today, Victor Bustos joins us as the Co-founder and COO of Refoxy Pharma. Refoxy is a biotech startup whose goal is not to extend the human lifespan but primarily to extend health. Basically, Refoxy aims to keep people healthy for as long as possible, which is both noble and challenging in itself, right? Initially, Victor was working in academia, but then he was motivated by the fact that life seemed too short coupled with him having read studies on how it was possible to change how long and how healthy people could live. Thus, Refoxy Pharma was born. Pivoting from the academe to creating a startup, however, was no easy feat, so Victor had some amazing insights and lessons to share with us about his journey from PhD student to startup founder. You won’t want to miss what h
%PDF-1.6 %���� 1 0 obj >/OCGs[30 0 R]>>/Pages 3 0 R/Type/Catalog>> endobj 2 0 obj >stream application/pdf ELSF Agenda 2023-03-02T09:33:03+01:00 2023-03-02T09:33:03+01:00 2023-03-02T09:33:03+02:00 Adobe Illustrator 26.5 (Windows) 256 132 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAhAEAAwER
AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAA
🎙️ NEW PODCAST EPISODE OUT NOW! Join us for a conversation with Simon Foster, industry marketing manager at LYB, as he discusses the launch of our Purell portfolio in North America, a major step forward in supporting the healthcare industry. In this episode, Simon shares how the Purell launch builds on the LYB legacy as a pioneer in healthcare polymers and why this portfolio delivers more than just performance. “Purell stands out because it is more than just performance, it allows us to give our customers peace of mind that we have taken additional steps in our operations to ensure quality of
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $38,902 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
A two-day event at the Stanford School... - Stanford Medicine Facebook Log In Stanford Medicine's Post Stanford Medicine Verified account May 3, 2023 · Shared with Public A two-day event at the Stanford School of Medicine brought together investors, regulators, company executives and scientists to discuss the most productive ways for them to work together. #Biology #Science #Research med.stanford.edu At Stanford Medicine symposium, Nobelists stress importance of basic research to drug discovery All reactions: 12 1 comment 1 share Like Comment Most relevant Redu An https://clothes-lines.sh
Tackling pulmonary fibrosis: B… - Beyond Biotech - the podcast from Labiotech - Apple Podcasts Search Home New Top Charts Search December 12, 2025 39 min Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach Beyond Biotech - the podcast from Labiotech Play In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company’s headquarters in Germany, joined as a scholarship student more than 20 years ago, and never really left – and you’ll hear why he still
%PDF-1.4 %���� 12691 0 obj > endobj xref 12691 56 0000000016 00000 n 0000005472 00000 n 0000005639 00000 n 0000009689 00000 n 0000009741 00000 n 0000009794 00000 n 0000009847 00000 n 0000009973 00000 n 0000011261 00000 n 0000011581 00000 n 0000012375 00000 n 0000013055 00000 n 0000013373 00000 n 0000013743 00000 n 0000013842 00000 n 0000014451 00000 n 0000015238 00000 n 0000015942 00000 n 0000016068 00000 n 0000016162 00000 n 0000016751 00000 n 0000017416 00000 n 0000017515 00000 n 0000018080 00000 n 0000018702 00000 n 0000019414 00000 n 0000019500 00000 n 0000019931 00000 n 0000020472 00000 n … ,)�ʹ{�����B� a8��SM ݁�!����I?�� Ǝ���g|�(����������$�0/XNu�����\����� Fs�V�Rfp/̦��C�G"�?�R�htʘl�H>�*�4�'ue��N.�����X��a"�s ���ٌ�@�`#g8�� �cs�'���[i6�Ȯ�yq�+?[�f8�՛!�[[ӄg_ƥ� �霗 =��+SY��a�g�������xn8j�&V�EML�B a�?1�;��4��$�U���%�&V �goz���E7 �V�kG�Rc��b{7J��x�,l5O��3~�`��m]=p =W���?�7 �9��Ӑ�W= �,1��Ȥ� ~�7Al-Pg&dc�� ��V�� �7�[Y@��� �s�ݽ0r���π:uJ��NY�7�5D��@��;u�D�W�y������Ǯ7?N�j�}Y���~Ǯ1����I� ]÷O�U5ɪ�Yu��eS��~�V�&(!��U$o� … S���Y���/4�Uld���� *-����-[Z��+;I'�ٹfT(rF��=)ؖ�Z��:5�W�Ij�Ⱦ_�������$;%���RFp���I�p8�5]��#�Dž77�C7[�O lJ�U`����Sr�E+o�ִ�|�O RHI*��`H!O��9�c���ܱ��89�EQ���l�BҼ˛�,�G��Rr#&���a��A�N��I��9�uA�Tn� 2 ����i�b�ޱ-�12JA�ǖG�T���߭I!�Ɲ�&�-���L�ѕ��}�Ǩ��=z�Y�e���߱z�|f����n�irJLf�cb�a��qjV ��cm��+��:i�%���8���x��4 +* �!��9U�.��U ���4���z��$v��a��O_�s"�ȭ��(���N:����mpe,��ٜ�e��%�3 I�F�c�y���:`u���M0r��8 �m����$3� ��ˇ�+��Nð�zU.�T�v�.�)*�� 5��rp=�U … �6�\��2ܽ��ep����׀Kg&˄�A�5� WeG ���R��~�t}� endstream endobj 7 0 obj >stream application/postscript Impression Benjamin TOURBIER 2014-01-07T12:02:42+01:00 2014-01-07T12:02:42+01:00 2014-01-07T12:02:41+01:00 Adobe Illustrator CS5 xmp.iid:1D8F2BF28A77E31190B6E60A9968925F xmp.did:1D8F2BF28A77E31190B6E60A9968925F uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:6f945305-61b0-b244-bf48-d2818106a34b xmp.did:FB7F11740720681188C6D6CD398E74C0 uuid:5D20892493BFDB11914A8590D31508 … B6E60A9968925F 2014-01-07T12:02:42+01:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator Print False False 1 1417.000000 591.000000 Pixels Cyan Magenta Yellow Black Groupe de nuances par défaut 0 Blanc CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Noir CMYK PROCESS 0.000000 0.000000 0.000000 1
4th Epithelial Mesenchymal Interactions in Lung Development & Fibrosis Conference | Fusion Conferences Menu Conferences Forthcoming Conferences Past Conferences Discover Fusion Sponsor Packages Submit New Conference About News FAQs My Details My Conferences Contact Us Conferences Forthcoming Conferences Past Conferences Discover Fusion Sponsor Packages Submit New Conference About News FAQs Contact Us Home Past Conferences 4 th Epithelial Mesenchymal Interactions in Lung Development & Fibrosis Conference Share Past Conference 4 th Epithelial Mesenchymal Interactions in Lung … bsp;Poster Submission - Expired • Registration & Payment Deadline - Expired Sign up for updates Synopsis Speakers Programme Grants Sponsors & Partners Venue & Location Gallery Conference History 4 th Epithelial Mesenchymal Interactions in Lung Development & Fibrosis Conference 07 Mar - 10 Mar 2026 • Playa Mujeres, Mexico Sign up for updates Sign up for updates Synopsis Speakers Programme Grants Sponsors & Part … t informed should further grants be released. Or, you are welcome to send in an application in advance, to be considered in the first instance should additional grants be released. Supported by Gold Sponsors Silver Sponsors Bronze Sponsors Endorsing Partners Media Partners Interested in sponsoring this conference? Contact us Venue & Location SLS Playa Mujeres SLS Playa Mujeres is a luxury all-inclusive resort located in the beautiful Playa Mujeres area near Cancun, Mexico … ed selectedImages.push(parseInt(el.id)) ); $nextTick(() => { $refs.downloadForm.submit() })" type=button > Download All Conference History 17 Feb - 20 Feb 2019 Epithelial Mesenchymal Interactions in Lung Development & Fibrosis Conference Melia Nassau Beach All Inclusive, Bahamas Learn More 19 May - 22 May 2022 2 nd Epithelial Mesenchymal Interactions in Lung Development & Fibrosis Conference Fiesta Americana Condesa Cancun All Inclusive, Mexico Learn More 04 Oct - 07 … , you can sign up for updates here and our team will keep you updated regarding deadline reminders and grant opportunities relating to this meeting only. Name* Email* All personal data submitted herein are processed in accordance with UK data protection legislation. Sign me up Gold Sponsors Silver Sponsors Bronze Sponsors Endorsing Partners Media
Press release Archives - BioVox Skip to content Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders Wallonia Luxembourg The Netherlands Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary … science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders Wallonia Luxembourg The Netherlands Subscribe Calendar About Learn more about BioVox Contact Calendar About Learn more about BioVox Contact Search Subscribe Calendar About Learn mor … re about BioVox Contact Calendar About Learn more about BioVox Contact Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders W … ine Regional news Belgium Flanders Wallonia Luxembourg The Netherlands Field of application Agrofood Biomedical/pharma Environment/sustainability Personal/public health Veterinary science Focus on Discovery & research Finance & investment Industrial application Technology & digital innovation Content type Article Interview News Opinion Press release Showcase BioVox Biovia QbD Group V-Bio Ventures SciMingo JnJ Innovative Medicine Regional news Belgium Flanders W … s Wallonia Luxembourg The Netherlands Search News , Press release April 7, 2026 Fund+ Portfolio Company Tubulis to be Acquired by Gilead for BioVox • Fund+ portfolio company Tubulis will be acquired by Gilead for an upfront payment of USD 3.15 billion, with up to USD 1.85 billion in additional milestone payments • Tubulis’ next-generation ADC pla
Refoxy Pharmaceuticals Raises €9.1M in Seed Extension | Life Sciences VCLink LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agre … has raised €9.1M in a Seed extension round led by Boehringer Ingelheim Venture Fund (BIVF), with participation from Apollo Health Ventures , NRW.Venture, and HTGF | High-Tech Gründerfonds . The funding will help Refoxy develop novel therapeutic medicines focused on fibrotic disorders like idiopathic pulmonary fibrosis (IPF) and expand its discovery platform, F.act finder. FinSMEs https://lnkd.in/gtPHGDvP #lifesciences Refoxy Pharmaceuticals Raises €9.1M in Seed Extension htt
Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis – MAJUNKE.com Zum Inhalt springen EQUITY GUIDE Marktteilnehmer DEAL NEWS Latest News Sponsoren Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis Dezember 4, 2024 Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. New financing will accelerate preclinical development of Refoxy’s lead program in … ced a €9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF) to advance the development of novel therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF). IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. It involves t
Cologne-based biotech startup Refoxy Pharmaceuticals secures €9.1M seed-extension | Vestbee Join here Join Vestbee Summer Pitch CEE Pitch to hundreds of VC funds and business angels Join here Join here News Insights Sectors Newsletter Events Platform News Insights Sectors Newsletter Events Vestbee Platform December 4, 2024 · 2 min read Joy Laoun News Editor, Vestbee Cologne-based biotech startup Refoxy Pharmaceuticals secures €9.1M seed-extension Cologne-based Refoxy Pharmaceuticals, focused on developing pre-clinical anti-aging and age-related disease therapies, has raised €9.1 million in see … ised €9.1 million in seed-extension funding led by Boehringer Ingelheim Venture Fund to accelerate the development of FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis. Launched in 2020 by Wolfgang Link and Victor Bustos, Refoxy Pharmaceuticals develops therapies that activate FOXO3, a key transcription factor regulating biological homeostasis. Using its proprietary F.act finder platform, the company identifies molecules to address complex diseases by modulating FOXO … ls of the deal The seed-extension round was led by Boehringer Ingelheim Venture Fund (BIVF), the strategic venture arm of Boehringer Ingelheim Corporation, which invests in science-driven startups worldwide. “We are thrilled to provide funding for Refoxy's research on FOXO3 activation as a promising novel therapeutic approach. This perfectly aligns with our mission to support breakthrough developments and deliver innovative therapies to patients in need in the field of IPF," … atform The round was supported by True Collective and the Export and Investment Fund of Denmark (EIFO). Romanian-founded firm Almetra raises $19M Series A led by blisce The Series A round was led by Blisce, with participation from NAP, Merantix, Robin Capital, Underline Ventures, and Critical Ventures. Wayout International raises $2.7M to scale water infrastructure platform The round saw backing from both existing shareholders and new strategic investors with significant indu … atform The round was supported by True Collective and the Export and Investment Fund of Denmark (EIFO). Romanian-founded firm Almetra raises $19M Series A led by blisce The Series A round was led by Blisce, with participation from NAP, Merantix, Robin Capital, Underline Ventures, and Critical Ventures. Wayout International raises $2.7M to scale w
Refoxy Pharma | The Org Platform Enrich Pricing Log in Sign up Refoxy Pharma 0 followers Refoxy Pharma is a pre-clinical stage biotechnology company developing medicines for the treatment and prevention of aging and aging-associated diseases. Industries Biotechnology , Health & Wellness + 2 Headquarters Cologne, Germany Employees 1-10 Links Org chart Teams Offices Positions ( 9 ) Unverified Org chart Victor Bustos Co-founder and CEO 4 Victor Bustos Collapse IB Inder Bhamra Scientific Advisor 2 Sarah N. Executive Assistant To CEO 0 Teams Board Governance 3 people · 0 jobs DV Drug Developm
Refoxy Pharmaceuticals GmbH - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 Ne … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Refoxy Pharma Skip to content Portfolio Investors Team News & Events Login My pitch Deutsch English Portfolio Investors Team News & Events Metanavigation About us Career Portfolio Jobs ESG Contact Login 2024 Backed by HTGF since Unternehmen ansehen Refoxy Pharma Life Sciences Pharmaceuticals Rejuvenation North Rhine-Westphalia Key Facts Life Sciences Pharmaceuticals Rejuvenation North Rhine-Westphalia Invested since 2024 Based in Berlin About the company Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master … recision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs. to Scopis Unternehmen ansehen 2016 Signatope R&D Tools Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein … timOS Unternehmen ansehen 2022 C-mo Digital Health C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential … to C-mo Unternehmen ansehen 2017 KSK Diagnostics Exit Life Sciences KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to
Boehringer leads $10 million Refoxy funding | Biotechnology | The Pharmaletter Saturday 27 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardi … s ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. The money will enable the pre-clinical-stage biotech to advance its lead program targeting idiopathic pulmonary fibrosis (IPF) and expand its proprietary FOXO3 platform to address other age-related diseases. This article is accessible to registered users, to continue reading please register for free . A free trial will give you acce
Excited to announce that Refoxy Pharmaceuticals has successfully closed a €9.1 million seed-extension financing round! 🎉 This funding, led by Boehringer Ingelheim Venture Fund with participation… | Refoxy Pharma | 22 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your … extension financing round! 🎉 This funding, led by Boehringer Ingelheim Venture Fund with participation from Apollo Health Ventures , NRW.BANK , and HTGF | High-Tech Gründerfonds , will accelerate our preclinical development of novel FOXO3 therapeutics for idiopathic pulmonary fibrosis and other age-related diseases. A big thank you to our investors for their trust and support as we continue to advance our mission of developing treatments for chronic, age-related diseases. ht … Asian markets. With a proven safety & efficacy profile, their Series A will fund global ph3 trials that are currently screening patients. The team guiding the programs' development includes Nihar Bhakta , Tracy Rodgers , DeAnne Reid , & Ashwin Ram . Crystalys Therapeutics look well positioned to fill an unmet need for treatment options in gout across The US & Europe. https://lnkd.in/erU6_qtD James Mackay is tending to 'unfinished business' with new gout biotech an
Refoxy Pharmaceuticals GmbH - Activating Healthy Aging Science Company Team News Contact Science Company Team News Contact Our Mission Our Mission Empowering Healthier, Longer Lives Through Innovation Empowering Healthier, Longer Lives Through Innovation Our vision is to transform how we treat age-related diseases — not by targeting isolated symptoms, but by addressing the underlying biology that drives them. Refoxy’s discovery platform focuses on FOXO3, a transcription factor that orchestrates the body’s natural defense mechanisms against stress, damage, and aging. By developing small molecul
Refoxy Pharmaceuticals GmbH - Activating Healthy Aging Science Company Team News Contact Science Company Team News Contact Innovative Biotech to Treat Aging Innovative Biotech to Treat Aging Innovative Biotech to Treat Aging We create advanced biotechnologies that combat age-related diseases, enhancing health and extending quality of life by addressing aging at its core. Learn more Our vision Our vision W e e m p o w e r h u m a n i t y t o a c h i e v e h e a l t h i e r , l o n g e r l i v e s b y p i o n e e r i n g i n n o v a t i v e t h e r a p i e s t h a t t a r g e t a g e - r e l a t
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
biology delivered - o2h discovery website Skip to content o2h discovery website o2h discovery – seeding new ideas in life science, tech and green … about company overview team ESG o2h community how we deliver news & insights news & press releases blogs posters newsletters white papers webinars brochures events exhibiting/attending events o2h Innovation Conference 2026 Bootcamps AIM squad Cambridge Wide Open Day Cambridge TechBIO Caucus Biotech Bikers o2h Chaitime Webinar culture & careers CITC TM o2h group integrated (drug discovery) Target Identification and Validat … life science patents and publications. He received the Young Scientist of India award from OPPI in 2010. Connect on linkedin Meet our team What our clients say Eran Seger CEO and Co-founder, Protai Bio We had a great experience working with o2h discovery on our Fragment libraries project. Their expertise in conducting fragment-based screening, targeting dual series threonine kinase on surface plasmon resonance, was impressive. The efficiency, productivity, and detailed commun … collaborations at o2h discovery Press Release o2h Discovery Expands Kickstarter Award to Support Peptide Therapeutics 07 May 26 News OutSee closes £2.5m seed funding round and establishes partnership with o2h discovery for lead drug target candidate 27 Jan 26 Press Release Launching o2h Kickstarter in “North America” to Support Early-Stage Biotechs in Advancing Drug Discovery Programs 06 Jan 26 speak to a member of our team Contact Us o2h discovery private limited
Looking back at the end of 2024, a few standout venture deals caught my attention across sectors like medical, finance, pharma, and defence. Check them out! Neurent Medical Founders/ Leaders: Brian… | John Clark LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any … nt: €9 million Investors: Claret Capital Partners , @Irish Strategic Investment Fund (ISIF) Galway-based Neurent Medical secured €9 million in growth capital to fund its expansion in the United States. 9fin Founders/ Leaders: Steven Hunter , Huss E. Investment: $50 million Investors: Highland Europe with participation from Spark Capital , redalpine , Seedcamp , @500 Startups and Ilavska Vuillermoz Capital . UK-based fintech start-up 9fin, specialising in debt research and inf … Wolfgang Link Investment: €9.1 million Investors: Boehringer Ingelheim Venture Fund German biotech startup Refoxy Pharmaceuticals raised a €9.1 million seed round. Dcycle Founders/Leaders: Juanjo Mestre Investment: €6 million Investors: Samaipata Dcycle, a Spanish startup offering a SaaS solution to help companies manage their sustainability data, secured €6 million in a seed round led by Samaipata. 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign … add a comment, sign in Preeti Mahara 8mo Report this post Meet Verge HealthTech Fund - Singapore based investors backing Seed, Series A companies. 🎯 Focus areas: Digital Therapeutics, Digital Health Platform, Diagnostics, Medical Device, AI and Data Analytics Why they stand out: Verge HealthTech Fund is an early-stage venture capital firm investing globally in impactful healthtech startups. They focus on technologies solving large unmet needs in health and platforms reaching … e VIVES Partners featured in L'Echo , highlighting our ambition to launch a 4th fund dedicated to European science-based start-ups. Since 2004, VIVES has created 3 seed funds, all with the same goal: making science investable and impactful. “Over the past 12 months, we’ve participated in 6 financing rounds totalling nearly €200M, including NUCLID
%PDF-1.6 %���� 3472 0 obj >stream h��{mo G��~J���f�{�a1��6 �n�w8�X�=��Hh���wQ] Ye�-R�f���!v=]�YQUOEē/f5��*��2Ѯ�u i�q+��*V��U*�_Y?�������� ���8`�?�1�bWΚ�W���f�����M|�}�f�+�v�yXy����և�� ����6�m���ȇ 7�*�d�|��ƯBL�ǚ� ���MkWqH��l\E['���,N �[�a�5b3��ə߆�BS��~��� �ků �M~�q� ����M�!�*�R |�%���=��C2x� �3�) � � �]@-��aC�������됷�ƣ�6��������¸͓p%�-����LF�� �yސ̸���� ����2n��-y��yAh�� �����wן� �`��ec� �q�= �1 [�1���x��in8\���5��b��� zv�i�06��{�5n����avX{X ���y -��Z�r�v��cS�]��8�x��e���8� �f�� �RS ���{(�b�/Ϫ�f �Z��V c+ف2��W���? �������*F��!L�9��%��גU"O�6� … ��xK�f ��5,����|/翩r��8��.�gR�#��� ������$ϠT&we2�3(�وҘ����͠,&m%1Y3(�I�A)L� �`RfP�1�����ˠ��ϔ�dˠ�%Y�.�2(wI�A�K� �\eP�'��4��dɠ�%I�m��)2(�ɐAIL� Jb�cP� ������$�P�@`�bRcP���xܵm���ĤŠ$ �.%1I1*�ɉQILJ�Jb2bT����|�Ťè,.��'F�4�0*�I�Q)M&�JiaTJ��R�4��d���& F�490N9=�{M���~�p�~��>2�G���\ ��#s}d�8G��42�����ڇ}�q1N��Ƹ�ml9j7ur��^�����a�>Lׇ��tލz���uϺ��#li1j��Y��cܡ���:�ھ�����}�폯���'j����j�3���� 9�}�������J�5��WB�5��W���|�援�g��6 ����4�/R@[(�[��Ӝ�Ik������ �\�=�Y+�� … sh) 2025-07-08T12:29:07+02:00 2025-07-08T12:29:07+02:00 Adobe PDF library 17.00 application/pdf LOGO SEVERO OCHOA 25-31 1 False True 2253.000000 1271.300049 Pixels Black Grupo de muestras por defecto 0 uuid:67ff4f99-cb32-164a-808b-7f353ed2e878 proof:pdf xmp.did:d8d504fc-5a1d-4a78-926b-46baf848e4e9 uuid:734f77ba-c097-8542-9051-b81f95f313de xmp.iid:b08267c3-df83-4012-9cde-b0f70bf422a0 xmp.did:b08267c3-df83-4012-9cde-b0f70bf422a0 uuid:734f77ba-c097-8542-9051-b81f95f313de default … :00 macOS Versión 13.6.7 (Compilación 22G720) Quartz PDFContext, AppendMode 1.1 application/pdf endstream endobj 1165 0 obj > endobj 1166 0 obj >/Filter/FlateDecode/Height 154/Intent/Perceptual/Interpolate true/Length 4189/Name/X/Subtype/Image/Type/XObject/Width 299>>stream H��{XW��� ��"D�R����V]�J� �"X/�"h[/UA-��z�vu�뢮���V}�h}�������[ڬ"J��.� AH��L�@�ɀM4�y��w2��Μy� BO�(�~fB: >Rq�3��� ��أ����vvF�^K���Ԥ�P+�pR(c��*�� T�ٯ*��D�� f��A��N����os����۾O�z�$H � … ��">��I[�͆ %���mV �wJ��^�Z8����6�Y��� ?0�N���^�����.�����Hci�[X\�R����Y~wRfP��J���п�F�ПN�u�c"l�M�PPU[2L5�&a�����O ��x�E��DO���L�T�H��6�z��aX�M�mZS����m�� ە�����ka�!�˿?D��G���hS2h���n ão�8JX� ���7���"ů�q�o��H�f���6_;��������W K�]�7^xs~� ��q�5D��.���X��� �h�� �4��Q��p�SZj8����6��u g�!��3M#����; ��j���U�N]�P�K.}
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
The In Situ: Biology &... - The Rockefeller University Facebook Log In The Rockefeller University's Post The Rockefeller University May 26 · Shared with Public The In Situ: Biology & Society series at Rockefeller features expert panelists discussing how biomedical research intersects with policy, investment, and innovation. “I’m interested in how scientific institutions, government, and private capital can work together to support ambitious biological research and translate discoveries into societal benefit,” says Lauren Anderson Westcott, who researches the maintenance of chromat
The PHOTOKRETE team of CFM receives the award at the third edition of the CSIC Knowledge Transfer and Entrepreneurship Awards – CFM – Materials Physics Center Internet Explorer is not supported on this site. Use a modern browser like Firefox . EN ES EU Home About CFM History and Purpose Governance and Partnership MPC BERC Gender Equality and Diversity Job Offers Reports Facilities External Services External Advisory Committee CFM-MPC Sustainability Committee Contact & Location Research Lines Introduction Chemical Physics of Complex Materials Electronic Properties at the Nanosc … Quantum Breakfast TRANSPARENCY Intranet The PHOTOKRETE team of CFM receives the award at the third edition of the CSIC Knowledge Transfer and Entrepreneurship Awards Home / CFM News / The PHOTOKRETE team of CFM receives the award at the third edition of the CSIC Knowledge Transfer and Entrepreneurship Awards The PHOTOKRETE team of CFM receives the award at the third edition of the CSIC Knowledge Transfer and Entrepreneurship Awards Published: May 21, 2026 The PHOTOKRE … ards Published: May 21, 2026 The PHOTOKRETE project has officially received its award at the ceremony of the 3rd CSIC Knowledge Transfer and Entrepreneurship Awards. During the event, the team from CFM, composed of Guido Goracci, Silvia Arrese-Igor and Jorge Sánchez Dolado, collected the prize in the general Entrepreneurship category, consolidating institutional support for this initiative. The award ceremony took place in Alicante within the framework of the annual meeting o … Rogero, Director of CFM. Innovation against the “urban heat island” effect The award granted to PHOTOKRETE, presented ex aequo alongside the Refoxy Pharma initiative from IIBM-CSIC-UAM, represents important recognition of the work carried out by the CFM team composed of researchers Guido Goracci, Silvia Arrese-Igor and Jorge Sánchez Dolado. The initiative proposes the development of photonic mortars capable of reducing the temperature of urban surfaces and environments. Than
DQB Talks – Wolfgang Link – DQB Talks Skip to content DQB Talks Menu Upcoming Past Posted on by JASC DQB Talks – Wolfgang Link Seminar: Biochemistry | September 17 | 3:30 p.m.-4:30 p.m. | Room 1.3.33 A Speaker: Wolfgang Link , Principal investigator at CSIC, Instituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), Arturo Duperier 4. 28029-Madrid, Spain Non-Covalent CRM1 Inhibitors as a Precision Strategy Against Glioblastoma Host: Miguel Machuqueiro Glioblastoma (GB) is among the most lethal human cancers, driven by highly redundant and adaptive signaling netwo … -founder of exCELLerate S.L., semi-finalist VentureLab (Edition 2009-10), third prize Fundación Everis, Madrid 2010 and Refoxy Pharma, a biotech company dedicated to developing pharmaceuticals to target FOXO proteins. Notably, Refoxy has recently secured a substantial second investment round in collaboration with a prominent German pharmaceutical company. Dr Link acts as an expert evaluator for many international funding organisations and as a peer-reviewer for many prestigio … REFET) funded by the European Union, a pharma company (Bayer AG), an investment fund (Apollo Ventures) and a doctoral program (TubInTrain, EU). Dr Link participated in several COST actions (BM1204, CM1407, CA17104, IG17104) and organized international conferences and seminar series, e.g. Organizer/Chair Panel Discussion with Vera Gorbunova/Joris Deelen (December 2022), Webinar with Robert A. Weinberg, Whitehead Institute for Biomedical Research (June 2022). Importantly, the L … 5-20 2025-06-23 2025-09-17 2025-11-11 2025-11-14 2025-12-19 Upcoming 2026-02-02 Submit an event Proudly powered by WordPress
8 promising respiratory companies to watch in 2025 Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector A … ed a £26 million ($33.1 million) series B follow-on round , which allowed it to fund the phase 2a trial for ETD001. Insilico Medicine Technology: AI-developed small molecule Respiratory disease candidate: ISM001-055 Recent news: Signed a Revolving Loan Facility of up to $100 million with HSBC Artificial intelligence (AI) drug discovery company Insilico Medicine is focused on connecting biology, chemistry, and clinical trial analysis using next-generation AI
%PDF-1.7 %cleaned_by_fortinet 1 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageC/ImageI]/Properties >/XObject >>>/Rotate 0/Tabs/W/Thumb 4625 0 R/TrimBox[0.0 0.0 841.89 595.276]/Type/Page/PieceInfo /LastModified /NumberOfPageItemsInPage 3/NumberofPages 1/OriginalDocumentID /PageItemUIDToLocationDataMap >/PageTransformationMatrixList >/PageUIDList >/PageWidthList >>>>>>> endobj 2 0 obj [3 0 R 4 0 R 5 0 R 6 0 R 7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R 13 0 R 14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 1340 0 R 1341 0 R 1348 0 R] endobj 3 0 obj >/Border[0 0 0]/H/N/Rect[158.386 488.636 235.08 … fz�e��xU�>厛��4 J l�� /�N��'� Lf؝?�{F endstream endobj 22 0 obj >stream application/postscript Druck Nina Heyne 2019-12-11T15:38:41+01:00 2019-12-11T15:38:41+01:00 2019-12-11T15:38:41+01:00 Adobe Illustrator CC 23.0 (Macintosh) xmp.iid:94a74def-e903-4e86-af9c-bd77830e199a xmp.did:94a74def-e903-4e86-af9c-bd77830e199a uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:64861d47-4947-403e-b809-3494ea91bdb3 xmp.did:64861d47-4947-403e-b809-3494ea91bdb3 uuid:5D20892493B … 019-12-11T15:38:41+01:00 Adobe Illustrator CC 23.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator Print False False 1 297.000000 210.000000 Millimeters Cyan Magenta Standard-Farbfeldgruppe 0 Weiß RGB PROCESS 255 255 255 Schwarz RGB PROCESS 29 29 27 R=0 G=159 B=227 PROCESS 100.000000 RGB 0 159 227 R=3 G=78 B=162 PROCESS 100.000000 RGB 3 78 162 Graustufen 1 C=0 M=0 Y=0 K=100 RGB PROCESS 29 29 27 Adobe PDF library 10.01 endstream endobj … 27 Adobe PDF library 10.01 endstream endobj 23 0 obj > endobj 24 0 obj >stream application/postscript Druck Nina Heyne 2019-12-11T15:42:48+01:00 2019-12-11T15:42:48+01:00 2019-12-11T15:42:48+01:00 Adobe Illustrator CC 23.0 (Macintosh) xmp.iid:1de25bc7-45f5-42af-951b-f5a2244820c4 xmp.did:1de25bc7-45f5-42af-951b-f5a2244820c4 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:bfefc8d9-4c54-4892-9a49-2e0ef60a09a3 xmp.did:bfefc8d9-4c54-4892-9a49-2e0ef60a09a3 uuid:5D20892493B … 019-12-11T15:42:48+01:00 Adobe Illustrator CC 23.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator Print False False 1 100.000000 100.000000 Millimeters Cyan Magenta Standard-Farbfeldgruppe 0 Weiß RGB PROCESS 255 255 255 Schwarz RGB PROCESS 29 29 27 R=0 G=159 B=227 PROCESS 100.000000 RGB 0 159 227 R=3 G=78
%PDF-1.4 %���� 2950 0 obj > endobj xref 2950 15 0000000016 00000 n 0000013688 00000 n 0000013880 00000 n 0000013926 00000 n 0000013964 00000 n 0000014945 00000 n 0000015058 00000 n 0000015097 00000 n 0000015338 00000 n 0000015477 00000 n 0000016289 00000 n 0000016999 00000 n 0000017750 00000 n 0001849265 00000 n 0000000596 00000 n trailer ]/Prev 48678854>> startxref 0 %%EOF 2964 0 obj >stream hޤz X�W��� ��! �@�A� A�&`g,C; P�L�K�ڞ�� AD."���v�s� �jт2 �r�.Uj��hmGg�>{��� ݳ�s�y4k���.��~���"N����ˈ?��� !"d�����,� �0z&�!X,,]������П����*,��w�3���F`����w n��ܻ��/`��/���q�� … ��ﳰB}�y'����V6S��KP��N��� ��:E����%rG x�û´�.����H8����P�Ðm*�v�: �K�>�� RFp� o�s� xS[JJMHs��!Ԉ�$�U;��7�d�V����%T� ��yS��o�gx�� q% ��Ls3L���d�)3���IќWW�� �Ҽ�b�kHHR�B��HN������^��[2��ͳ�Am{�Q�"���5� �48G5TƤ�s��R��$�� �ҮG��*���J�]�ĕ6�CȐB�`���;'��[��ݲ�h��J��& � ��=yՐV� l�"D|����:�Ym�& �����jqL��ԅ�@���$ �����R�[J$(�4:F�����D_z��IZB�'��8�!-,����+�ƉH�� w��P �h�̪� }@u��d(�Lb����+�^9�m�a�Y%'�gv"gi���jG� Fgm�;��,�-���� �>���p … ���S�--?GCi�F�U���3[��*H+M��yA�3� q���Q���D���8B�ۊ:m��jUw���|tN!��wZ�RFP�bd�T�& Cq��t� 8�:B��aK_�kN���6�7 �b9Sb���,���J�2�J^`�����&`�#2�3Q�)�Q*����I�Jbc�@�p~�H�x��ԅ�b�9��#Y4�)J@ è��m����-�%E0T���F���9\(��͗H k�2Og���Vq�RZJ4� �)�)R�1W'n �X4IHۄ����K:{�QV�����a��eI�JPVP������l2J�XI!w���U�(nu�k�Rf_ղ����� >^{Z�p�o���N|���-���JR��� 0!#P���l&�nB[d�BA��$ ;�v�V}��Ќ;!2��U� �S;���ڲ}7�~o]*3�u�qj��� ��)IL�H�@1���ڹE� *\�e ROi��S"� !�� … ��t��~ ~�b,Mo�\����]B� �ѿ�Z�zD�}i��念!f��|��w��� U� u x@� '�����YX�p6�RFP@I�m��J9~h�L��m̋^ d�n�C%>����[� `�� ���z�-��*L��ʌ��\�,��K�p&��� `{�ho*�F�'��P���+@�0��{�K������p�\�o��T�g|������旨�H�6�����b1)ú)Rq�:��x6|ς���%��'`)�Z 9{��k���i����|�o���R-�. ���*L��� I�q~�>�.%:�R����µ��`8� e3قv"�aNd=��F�?�l�� �D'+m����P>�TڧҊx�v����P�֎�'a�豮��>r����I"��8�m0��A�|�6�Hk8�$Gt`�Բ� >����a#,�3���Ԃq$��X;��o��#�����{��jS�P���5)� ݷ��,�%� &8S�u])���|��E)%$ … g� ��d�J�!)Ke(%Di)(H�(� 3Tߤ�6źr����K��L��%;�$�h�+T��X��XF�%"If?�vتj��rfp�n�;��g��nA1W�Q� .T���2�2����hID�ˆe�:~���j ��xv����N[��he)��&>H�G.��s���F,� �*����S^c��� �bA���2O�T����sl�.AR ô� R�"PJ�3+! �$���^�X�OT��x&��^N�#�>���� ��������aNv��7� 3J�³�� k��'I���~B���%�t(u�4��0�(m�*7�O��. ���xGEY"� �c)��O,��Ƥʒ��w'N�jNӥ=Ô
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
🚀 Let's treat idiopathic pulmonary fibrosis (IPF) together! Refoxy Pharma is a preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of… | HTGF | High-Tech Gründerfonds LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can u … ced a €9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Health Ventures , NRW.Venture, and HTGF | High-Tech Gründerfonds . 🫁🔍 IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. It involves the buildup of scar tissue (fibrosis) in the lungs and progressively limits breathing capacity. Refoxy is taking a novel appr
Ep#46: Improving Healthy Longevity via Transcription Factors with Dr. Victor Bustos by @Oleksandr Yagensky · Zencastr Video Oops! Zencastr was unable to start because Javascript is disabled To fix this problem, check your browser's settings and enable Javascript Become a Creator today! Start creating today - Share your story with the world! Start for free 00:00:00 00:00:01 15 15 Play again Play next Create a free podcast Ep#46: Improving Healthy Longevity via Transcription Factors with Dr. Victor Bustos S3 E46 · Personalized Medicine Podcast 430 Plays 3 years ago Subscribe In this episode
🔬 Delighted to welcome Andrew Pierce to Refoxy Pharma as our Chief Scientific Officer. Andy brings two decades of deep, hands-on drug development experience across the Pharma and Biotech. What… | Dr. Victor Bustos LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at … on to our team. He expertly balances rigorous scientific inquiry with practical application, focusing on areas like biomarker-driven development and first-in-human programs. His extensive global experience spans the US, UK, Europe, and Asia-Pacific, and he thoughtfully embraces AI-enabled methods to enhance our translational decision-making. 🤖 Moreover, Andrew holds advisory positions with the UK Medical Research Council and the US National Cancer Institute, which speaks vol
Refoxy Pharmaceuticals sichert €9,1 Millionen Seed-Finanzierung | Startbase Javascript ist in deinem Browser deaktiviert Startbase benötigt Javascript, um Inhalte anzeigen zu können. Bitte überprüfe deine Browsereinstellungen und aktiviere die Javascript-Unterstützung für diese Website. Your browser is outdated and Startbase will not be displayed correctly. Please use a modern web-browser like Mozilla Firefox , Google Chrome , Safari or Microsoft Edge . Startbase.de Magazin News Refoxy Pharmaceuticals sichert €9,1 Millionen... Magazin Neuste Beiträge Themen-Übersicht News Ticker Venture Client … Millionen Seed-Finanzierung Top-Investoren dabei: Boehringer Ingelheim Venture Fund und Apollo Health Ventures unterstützen innovative Biotech-Lösung. News von Marc Nemitz · Stuttgart, 04. Dezember 2024 Prof. Wolfgang Link, Co-Founder Refoxy | (c) Refoxy Top-Investoren dabei: Boehringer Ingelheim Venture Fund und Apollo Health Ventures unterstützen innovative Biotech-Lösung. Köln, 4. Dezember 2024 – Das Biotechnologie-Unternehmen Refoxy Pharmaceuticals GmbH, das neuar … n €9,1 Millionen abgeschlossen. Die Runde wird vom Boehringer Ingelheim Venture Fund (BIVF) angeführt und durch Apollo Health Ventures, NRW.Venture und den High-Tech Gründerfonds ( HTGF ) unterstützt. Die Aktivierung von FOXO3 ist ein vielversprechender neuer Ansatz, der Patienten mit IPF dringend benötigte Behandlungsperspektiven eröffnen könnte. Dr. Niklas Czeloth, Investment Manager beim BIVF Das frische Kapital fließt in die präklinische Entwicklung des führenden Programm … hland und Europa. Investor 2010 Ingelheim a. Rhein Boehringer Ingelheim Venture Fund Strategic venture fund of the Boehringer Ingelheim Corporation. Investor 2016 Hamburg Apollo Health Ventures VC-Geber der sich auf Vermögenswerte konzentriert, die das Potenzial haben, altersbedingte Krankheiten wie Alzheimer, Herzkrankheiten, Sarkopenie, Gebrechlichkeit und Krebs zu behandeln, zu verhindern oder sogar... Ähnliche Beiträge News Startupnews zum Wochenende KW 26/26 Wo fließt ak
We are delighted to introduce Andrew Pierce as our new Chief Scientific Officer at Refoxy Pharma! 🎉 At Refoxy Pharma, our mission is to develop groundbreaking FOXO3-based therapeutics to tackle… | Refoxy Pharma | 39 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your … on to our team. He expertly balances rigorous scientific inquiry with practical application, focusing on areas like biomarker-driven development and first-in-human programs. His extensive global experience spans the US, UK, Europe, and Asia-Pacific, and he thoughtfully embraces AI-enabled methods to enhance our translational decision-making. 🤖 Moreover, Andrew holds advisory positions with the UK Medical Research Council and the US National Cancer Institute, which speaks vol
Refoxy Pharmaceuticals GmbH - Activating Healthy Aging Science Company Team News Contact Science Company Team News Contact Why FOXO3? Why FOXO3? FOXO3 is a Master Orchestrator FOXO3 is a Master Orchestrator FOXO3 is a Master Orchestrator Modulating FOXO3 is a promising strategy for treating age-related diseases because this protein is crucial in regulating cellular homeostasis, multi-organ responses to diverse forms of stress, and human health. Traditional drug development often focuses on single proteins or signalling pathways, achieving limited success for complex and multifactorial disorder
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Refoxy Pharma - Longevity List Sign in or Register Add a listing View all results No results Jobs Database More arrow_drop_down Clinical Trials Newsletter Coworking Events Blog Supporters About Add a listing opening tag is omitted --> tag --> Refoxy Pharma drugging FOXO transcription factor Website Profile prev next Website Bookmark Share prev next General Headquarters Berlin, Germany Founders & Team Victor Bustos Year Founded 2020 Number of employees 10 Company type Private company Investors Apollo Health Ventures Technical Details Aging Target De-regulated nutrient sensing Product modality s
IIBM & Society - iib.uam.es Wolfgang Link honored by CSIC for his spin-off Refoxy Pharma - iib.uam.es Navigation Skip to Content --> --> Intranet Contact Directory Español | English changed --> Instituto de Investigaciones Biomédicas Sols-Morreale changed --> IIBM Toggle Dropdown Welcome History Alberto Sols Gabriella Morreale Organization Committees Junior IIBM Funding Research Toggle Dropdown Programmes Publications Biocomp Tools Scientific Reports IIBM & Society Toggle Dropdown News Outreach Igualdad Empleo y Formación Video Gallery Events Toggle Dropdown Archivo de Seminarios Ciclo de … vents Toggle Dropdown Archivo de Seminarios Ciclo de conferencias Sols-Morreale Award Services Toggle Dropdown Scientific-Techical Services General Services Wolfgang Link honored by CSIC for his spin-off Refoxy Pharma IIBM & Society Wolfgang Link honored by CSIC for his spin-off Refoxy Pharma Wolfgang Link honored by CSIC for his spin-off Refoxy Pharma --> Wolfgang Link honored by CSIC for his spin-off Refoxy Pharma 22 May | 2026 The researcher’s track record highlights t … awardees in the 3rd CSIC Transfer and Entrepreneurship Awards. He received the prize in the Entrepreneurship category (General Category) for his outstanding track record leading the spin-off Refoxy Pharma . The award-winning nomination, titled “ From CSIC Research to the Global Market: Refoxy Pharma, a Success Story in Science-Based Entrepreneurship ,” highlights more than 20 years of basic research led by Dr. Link on FOXO proteins. A radical innovation against cellular
Refoxy Pharmaceuticals GmbH - Activating Healthy Aging Science Company Team News Contact Science Company Team News Contact Why FOXO3? Why FOXO3? FOXO3 is a Master Orchestrator FOXO3 is a Master Orchestrator FOXO3 is a Master Orchestrator Modulating FOXO3 is a promising strategy for treating age-related diseases because this protein is crucial in regulating cellular homeostasis, multi-organ responses to diverse forms of stress, and human health. Traditional drug development often focuses on single proteins or signalling pathways, achieving limited success for complex and multifactorial disorder
Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis - My Framer Site Science Company Team News Contact Science Company Team News Contact News Brain.space remakes the EEG for our modern Brain.space Brain.space remakes the EEG for our modern Brain.space Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its … ced a €9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF) to advance the development of novel therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF). IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. It involves t … ly IPF. Refoxy is based in Cologne, Germany. About Boehringer Ingelheim Venture Fund The Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in pioneering biotechnology companies with a focus on therapeutics in order to promote innovation in biomedical research. The BIVF seeks significant improvements in patient care through groundbreaking scientific findings and their clinical implementation, building long-term relationships with scientists and entrepreneurs. The BIVF has … lding long-term relationships with scientists and entrepreneurs. The BIVF has a fund volume of EUR 350 million and refinances itself as an evergreen fund. Its partners benefit from the fund´s extensive experience in the fields of drug discovery, science and management. The BIVF currently serves a portfolio of more than 40 companies. About Apollo Health Ventures Apollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-drive … ents and venture creation. About NRW.Venture NRW.Venture is the venture capital fund of NRW.BANK. Together with private-sector investors, NRW.Venture invests up to 15 million euros of equity in young, innovative and often technology-oriented companies over several financing rounds – typically from the second round onwards – with NRW.BANK taking a
IIBM y Sociedad - iib.uam.es Wolfgang Link, premiado por el CSIC por su spin-off Refoxy Pharma - iib.uam.es Navegación Saltar al contenido --> --> Intranet Contacto Directorio Español | English changed --> Instituto de Investigaciones Biomédicas Sols-Morreale changed --> IIBM Toggle Dropdown Bienvenida Historia Alberto Sols Gabriella Morreale Organización Comités Junior IIBM Financiación Investigación Toggle Dropdown Programas Publicaciones Herramientas Biocomputación Memorias científicas IIBM y Sociedad Toggle Dropdown Noticias Divulgación Igualdad Empleo y Formación Galería de vídeos Eventos
IIBM & Society - iib.uam.es Refoxy Pharma, co-founded by Wolfgang Link, secures €9.1 million - iib.uam.es Navigation Skip to Content --> --> Intranet Contact Directory Español | English changed --> Instituto de Investigaciones Biomédicas Sols-Morreale changed --> IIBM Toggle Dropdown Welcome History Alberto Sols Gabriella Morreale Organization Committees Junior IIBM Funding Research Toggle Dropdown Programmes Publications Biocomp Tools Scientific Reports IIBM & Society Toggle Dropdown News Outreach Igualdad Empleo y Formación Video Gallery Events Toggle Dropdown Archivo de Seminarios Ciclo … vents Toggle Dropdown Archivo de Seminarios Ciclo de conferencias Sols-Morreale Award Services Toggle Dropdown Scientific-Techical Services General Services Refoxy Pharma, co-founded by Wolfgang Link, secures €9.1 million IIBM & Society Refoxy Pharma, co-founded by Wolfgang Link, secures €9.1 million Refoxy Pharma, co-founded by Wolfgang Link, secures €9.1 million --> Refoxy Pharma, co-founded by Wolfgang Link, secures €9.1 million 06 Feb | 2025 Refoxy Pharmaceuticals Gmb … ny has secured €9.1 million in funding, led by the Boehringer Ingelheim Venture Fund (BIVF) with participation from other investors, including Apollo Health Ventures, NRW.Venture Bank, and High-Tech Gründerfonds (HTGF). FOXO3 holds significant therapeutic potential in age-related diseases such as idiopathic pulmonary fibrosis (IPF). Refoxy has developed a discovery platform to identify FOXO3 activators, including several chemical series, termed ‘RP,’ which activate FOXO3 and
Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3 Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3 J Gerontol A Biol Sci Med Sci . 2022 Aug 12;77(8):1485-1493. doi: 10.1093/gerona/glab265. Authors Lucia Jimenez 1 , Andreia Silva 2 3 4 , Giampaolo Calissi 1 , Inês Grenho 2 3 4 , Rita Monteiro 2 3 4 , Victor Mayoral-Varo 1 , Carmen Blanco-Aparicio 5 , Joaquin Pastor 5 , Victor
Victor Bustos - Co-founder and CEO at Refoxy Pharma | The Org Platform Enrich Pricing Log in Sign up Refoxy Pharma Victor Bustos Unverified Victor Bustos Co-founder and CEO Contact Victor Bustos is a seasoned professional in the fields of biotechnology and pharmaceutical innovation, currently serving as Co-Founder and CEO of Refoxy Pharma since July 2020. Previously, Victor Bustos held the position of Entrepreneur-in-Residence at Apollo Health Ventures from August 2018 to July 2023. Prior to this entrepreneurial journey, Victor Bustos conducted postdoctoral research and completed a PhD at th
Victor Bustos, Refoxy Pharma–A Call to Lead @LifeScience ORG – Apple Podcasts Search Home New Top Charts Search 18 February 29 min Victor Bustos, Refoxy Pharma A Call to Lead @LifeScience ORG Play Why does the perception of facts matter when talking to investors? How do you attract a US-based chair to a European company’s board? And what are the advantages of running a virtual biotech with no labs of its own? Today, I’m joined by Victor Bustos, CEO of Refoxy Pharma. Refoxy is a "virtual biotech" located in Cologne, Germany, and is developing small-molecule drugs for the treatment of age-relate
Scientific innovation... - The New York Academy of Sciences Facebook Log In The New York Academy of Sciences's Post The New York Academy of Sciences May 21 · Shared with Public Scientific innovation and private capital are increasingly shaping one another, and our recently wrapped event series highlighted just how important that intersection has become. The Private Capital and Discovery: Strategic Investing in Scientific Innovation series brought together leaders across AI, quantum computing, climate tech, and health innovation to examine the opportunities and challenges driving investmen
Steering Committee - BioFIT Skip to content December 10 th & 11 th , 2026 15 th edition MARSEILLE, FR Linkedin 0 items 0 items 0 items Main Menu Menu Discover BioFIT BioFIT at a glance Organisers Steering Committee BioFIT x MedFIT News Press & Communication kit Programme Conference sessions Pitch sessions Start-up Slams Research & Licensing Partnerships Animal Health Presentations Previous edition Partnering One-to-one meetings Networking evening BioFIT 2025 partnering platform Participants Who will you meet? Supporters / Media Previous edition Exhibition Exhibition fees 2026 Exh … n Amsterdam. Juliette works across funds but is mainly involved in the Dementia Fund. Prior to joining EQT, Juliette worked as an Analyst at 4BIO Capital in London, UK. Prior to 4BIO Capital, Juliette was an Investment Fellow at M Ventures in Amsterdam. Juliette holds a PhD from the University of Cambridge and a Master in Neuroscience from King’s College London. JULIETTE LEE Vice President EQT Life Sciences JÜRGEN WALKENHORST Globe Linkedin Twitter Facebook Instagram JÜRGEN W … d is an Associate based in Paris. She is part of the Kurma Growth Opportunities Fund, which aims to invest into maturing European companies, across the Biotech and HealthTech sectors. Maylis is a scientist by training, she graduated from King’s College London in Biomedical Science with a focus on immuno-oncology, and Essec Business School in Strategy and Finance. MAYLIS DESCHAMPS Associate Kurma Partners OLIVIER LOGET Globe Linkedin Twitter Facebook Instagram OLIVIER LO … arch institutes and university hospitals to help advance their projects towards application. Before joining Ascenion, Rebekka spent over seven years at Sanofi, where she held various medical and marketing roles managing different Rx products in Germany and Switzerland. In her last position as Brand Manager at Sanofi, she was responsible for the company’s hematology portfolio and led the launch of a new multiple myeloma therapy in the German market. Rebekka holds a PhD in Mole … egan as a medicinal chemist at Novartis Animal Health, following a postdoctoral fellowship at Stanford University and earning a PhD in organic chemistry from the University of Basel. He has extensive experience spearheading global projects from discovery through development and regulatory submission. STEVE NANCHEN Senior Director Head of Partners
Anne Marije van Harten - Apollo Health Ventures | LSX USA Congress Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Executive Partnering Congress Sept 23-24, Forums Sept 22, 2026 BCEC, Boston, USA Home home Agenda expand_more Day 0 Day 1 D … SA Home home Agenda expand_more Day 0 Day 1 Day 2 Speakers Showcase expand_more Apply Showcase Agenda Investor Feedback Panel Investors expand_more Investor Criteria Syndication Drinks 2025 Investor Attendees Partnering expand_more PartneringONE Partnering Upgrades Networking expand_more Speed Networking Investor Syndication Drinks Sponsor & Partner expand_more Partner With Us Sponsors Partners Sponsorship Brochure More expand_more Plan Your Visit Floorplan Biotech Week B
Refoxy Pharmaceuticals | | The Pharmaletter Saturday 27 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene T
Idiopathic pulmonary fibrosis promising drugs: FOXO3 and beyond Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Brows … illion ($9.58 million) in a financing round led by Boehringer Ingelheim Venture Fund. It will use the funds to accelerate the preclinical development of its IPF candidate RP-01, which is designed to target FOXO3, a “pivotal master regulator of healthy aging,” according to Victor Bustos, chief executive officer (CEO) and co-founder of Refoxy Pharma. “Our efforts have been centered on identifying pharmacological activators of FOXO3 using our proprietary platform, F.act Fi … track, and underscores a potentially novel angle to tackle IPF.” Boehringer to submit NDA for nerandomilast for IPF While RP-01 is expected to hit the clinic in 2027, there are quite a few drugs in the clinic at the moment, like German pharma giant Boehringer Ingelheim’s nerandomilast. It is an oral inhibitor of phosphodiesterase 4B (PDE4B), a protein that regulates cellular signaling pathways. The drug hit the primary endpoint in a phase 3 trial in September, which measured … unt of air a person can let out after inhaling deeply. Now, Boehringer plans to submit a new drug application (NDA) with the FDA as well as other health regulators worldwide. If approved, it will compete with Boehringer’s other IPF drug nintedanib, sold under the brand name Ofev, and Roche’s Esbriet (pirfenidone). This actually comes after several failed clinical attempts to beat Ofev and Esbriet. These include California-based FibroGen’s anti-CTGF antibody pamrevlumab,
Refoxy lands €9.1m to advance FOXO3 therapeutics for age-related diseases | Dr. Victor Bustos | 15 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Cologne-based Refoxy Pharmaceuticals Secures €9.1 Million to Advance Anti-Aging Therapies Led by Algarve Biomedical Center Research Collaborator • ABC Ri Skip to content ABOUT US RESEARCH HUBS TRAINING POST-DOCTORAL PHD MASTER POSTGRADUATE UNDERGRADUATE OTHER COURSES (Soon) GENESIS OUTREACH HIGHLIGHTS NEWS EVENTS ALL EVENTS CONFERENCES/CONGRESSES SEMINARS WORK WITH US TEAM CONTACTS Menu ABOUT US RESEARCH HUBS TRAINING POST-DOCTORAL PHD MASTER POSTGRADUATE UNDERGRADUATE OTHER COURSES (Soon) GENESIS OUTREACH HIGHLIGHTS NEWS EVENTS ALL EVENTS CONFERENCES/CONGRESSES SEMINARS WORK WITH US TEA … tension funding round. The funding, spearheaded by Boehringer Ingelheim Venture Fund, will bolster the company’s efforts to develop groundbreaking FOXO3 therapeutics, particularly targeting Idiopathic Pulmonary Fibrosis (IPF). Founded in 2020 by Wolfgang Link, a distinguished researcher affiliated with the Algarve Biomedical Center Research Institute, and Victor Bustos, Refoxy Pharmaceuticals is at the forefront of harnessing the therapeutic potential of FOXO3. This vit
Refoxy Pharmaceuticals GmbH - Activating Healthy Aging Science Company Team News Contact Science Company Team News Contact Science with Heart, Collaboration with Purpose Science with Heart, Collaboration with Purpose At Refoxy, we’re building more than a company — we’re building a culture where deep science, shared purpose, and open collaboration come together to drive innovation. At Refoxy, we’re building more than a company — we’re building a culture where deep science, shared purpose, and open collaboration come together to drive innovation. "Science with Heart, Collaboration with Purpose"
Refoxy Pharmaceuticals GmbH - Activating Healthy Aging Science Company Team News Contact Science Company Team News Contact Reimagining Healthy Aging At Refoxy, we’re developing next-generation medicines to treat age-related diseases and extend the number of years people can live in good health. Our work targets FOXO3, a master regulator of cellular resilience, to unlock better outcomes for patients facing some of today’s most challenging chronic conditions. At Refoxy, we’re developing next-generation medicines to treat age-related diseases and extend the number of years people can live in good
Virtual Biotech Entrepreneurship: Refoxy Pharma's Agile Approach | LifeScience ORG posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s … �𝗺 𝘁𝗼 𝗮𝗽𝗽𝗹𝘆?” ➡️ Swipe through the slides for the answers. The BioSTART Fellowship provides €𝟮𝟬–𝟯𝟬𝗞 𝗶𝗻 𝗻𝗼𝗻-𝗱𝗶𝗹𝘂𝘁𝗶𝘃𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴, mentorship, and structured support to help transform promising biotech ideas into 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗲𝗱 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁. 📅 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗮𝗱𝗹𝗶𝗻𝗲: 𝟭𝟲 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 More information and applications: biostart.bioinnovation.gr If you know a researcher, scientist, or early-stage founder … oward global expansion; MIT Innovator Under 35, EU Top 50, and Innovation Radar Prize 2023 awardee. 2. Luis Ruiz-Avila - Biotech entrepreneur and CEO who has built and funded 15+ ventures, raising over €40M. 3. Pilar Puig-Sàrries, PhD - Molecular biologist and venture builder specialising in early-stage child health innovation across Europe. 4. Uri Fligil - Global commercial strategist driving healthcare growth and go to market execution. 5. Anieke Lamers - Healthcare VC and
Refoxy capta 9,1 millones de euros para avanzar en terapias contra la fibrosis pulmonar | Salud35 --> Regístrate ÚLTIMAS NOTICIAS 07:00h La exposición a contaminación durante el embarazo se asocia con peores resultados cognitivos tempranos 22:30h Avances en la detección precoz del cáncer de endometrio: la biopsia óptica podría sustituir a los métodos tradicionales 17:30h Caen las muertes por cáncer de cérvix un 80%: así ha cambiado el panorama la vacunación del VPH 17:00h El estrés y cenar tarde son factores relacionados con problemas intestinales Ver Más > Newsletter Iniciar Sesión Naciona
Refoxy Seed Finanzierung Skip to content Portfolio Investors Team News & Events Login My pitch English Portfolio Investors Team News & Events Metanavigation About us Career Portfolio Jobs ESG Contact Login ⟨ Back to overview News 4 December 2024 Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis ⌵ News Article Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. New financing will accelerate preclinical de … ced a €9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF) to advance the development of novel therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF). IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. It involves t … e I Germany [email protected] www.refoxy.com About Boehringer Ingelheim Venture Fund The Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in pioneering biotechnology companies with a focus on therapeutics in order to promote innovation in biomedical research. The BIVF seeks significant improvements in patient care through groundbreaking scientific findings and their clinical implementation, building long-term relationships with scientists and entrepreneurs. The BIVF has … lding long-term relationships with scientists and entrepreneurs. The BIVF has a fund volume of EUR 350 million and refinances itself as an evergreen fund. Its partners benefit from the fund´s extensive experience in the fields of drug discovery, science and management. The BIVF currently serves a portfolio of more than 40 companies. About Apollo Health Ventures Apollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-drive … ents and venture creation. About NRW.Venture NRW.Venture is the venture capital fund of NRW.BANK. Together with private-sector investors, NRW.Venture invests up to 15 million euros of equity in young, innovative and often technology-oriented companies over several financing rounds – typically from the second round onwards – with NRW.BANK taking a
Eli Harrell - Victor Bustos, COO and co-founder of Refoxy... Facebook Log In Eli Harrell's Post Eli Harrell September 13, 2022 · Shared with Public Victor Bustos, COO and co-founder of Refoxy Pharma, discussed what the company is doing to follow biology. Check out the most recent episode of Products with Purpose! #purposedriven #agingbiology #entrepreneur #biotech #investment All reactions: 2 1 comment Like Comment Most relevant Most relevant is selected, so some comments may have been filtered out.
Dr. Victor Bustos - COO at Ref... - Dr. What Now? - Apple Podcasts Buscar Inicio Novedades Lo más escuchado Buscar 26 de septiembre de 2023 43 min Dr. Victor Bustos - COO at Refoxy Pharma and Entrepreneur-in-Residence at Apollo Health Ventures Dr. What Now? Reproducir From investing in age-related healthcare companies to co-founding one. In this episode Inês chats with Victor Bustos, co-founder and COO of Refoxy Pharma, about venture capital & biotech at the interface of aging research. “Whatever your next step could be, choose your boss not the job” “The most important thing
Victor Bustos, Refoxy Pharma - A Call to Lead @LifeScience ORG Episode 3 Victor Bustos, Refoxy Pharma Published on: 19th February, 2026 Why does the perception of facts matter when talking to investors? How do you attract a US-based chair to a European company’s board? And what are the advantages of running a virtual biotech with no labs of its own? Today, I’m joined by Victor Bustos, CEO of Refoxy Pharma. Refoxy is a "virtual biotech" located in Cologne, Germany, and is developing small-molecule drugs for the treatment of age-related disease. About LifeScience ORG It’s no secret that Europe i
Our CEO and Co-Founder, Dr. Victor Bustos , joined the A Call to Lead podcast by LifeScience ORG hosted by David Kirk to talk about why building a virtual biotech is a strategic choice, not a… | Refoxy Pharma LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti … �𝗺 𝘁𝗼 𝗮𝗽𝗽𝗹𝘆?” ➡️ Swipe through the slides for the answers. The BioSTART Fellowship provides €𝟮𝟬–𝟯𝟬𝗞 𝗶𝗻 𝗻𝗼𝗻-𝗱𝗶𝗹𝘂𝘁𝗶𝘃𝗲 𝗳𝘂𝗻𝗱𝗶𝗻𝗴, mentorship, and structured support to help transform promising biotech ideas into 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗲𝗱 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁. 📅 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗮𝗱𝗹𝗶𝗻𝗲: 𝟭𝟲 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 More information and applications: biostart.bioinnovation.gr If you know a researcher, scientist, or early-stage founder … oward global expansion; MIT Innovator Under 35, EU Top 50, and Innovation Radar Prize 2023 awardee. 2. Luis Ruiz-Avila - Biotech entrepreneur and CEO who has built and funded 15+ ventures, raising over €40M. 3. Pilar Puig-Sàrries, PhD - Molecular biologist and venture builder specialising in early-stage child health innovation across Europe. 4. Uri Fligil - Global commercial strategist driving healthcare growth and go to market execution. 5. Anieke Lamers - Healthcare VC and
Victor Bustos, Refoxy Pharma - A Call to Lead @LifeScience ORG | Podcast on Spotify
An interesting podcast with Dr. Victor Bustos of Refoxy Pharma on the hard but rewarding leap into entrepreneurship. His story tells of a scientist learning to provide compelling stories, build peer… | Christopher Yohn, Ph.D. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your